EASL 2020 EASL 2020 conference bulletinRead our special conference bulletin in English, Spanish, Russian, French & Portuguese. Gamal Shiha of the Egyptian Liver Research Institute and Hospital presenting to EASL 2020.Hepatocellular carcinomaModels can help predict liver cancer in people cured of hepatitis C. Dr Thomas Marjot of the University of Oxford presenting to EASL 2020.COVID-19International registries provide more information about COVID-19 and liver disease. infohep news Experimental treatments for NASH/NAFLD Cotadutide improves metabolic and liver biomarkers in people with NAFLD and diabetes Liz Highleyman / 26 October 2020 Cotadutide, an experimental therapy that alters glucose and lipid metabolism, led to weight loss and improvements in metabolic, cardiovascular and liver fibrosis biomarkers in overweight people with diabetes and fatty liver disease, but ... Experimental treatments for NASH/NAFLD Experimental NASH treatments: Gilead candidates miss primary endpoint but show some benefits Liz Highleyman / 20 October 2020 Combinations of experimental drugs for non-alcoholic steatohepatitis (NASH) failed to meet a study's primary endpoint by significantly improving liver fibrosis without worsening NASH, but one combination in particular – firsocostat plus ... Hepatocellular carcinoma (HCC) Models can help predict liver cancer in people cured of hepatitis C Liz Highleyman / 17 September 2020 Three new methods using readily available clinical parameters can help predict who will develop hepatocellular carcinoma (HCC) after achieving sustained virological response to hepatitis C treatment, according to studies presented at the recent 2020 Digital ... Coronavirus International registries provide more information about COVID-19 and liver disease Liz Highleyman / 17 September 2020 People with advanced liver cirrhosis are more likely to develop severe COVID-19 complications and to die from it, but those who have received liver transplants do not appear to be at greater ... Experimental treatments for NASH/NAFLD Aldafermin reduces liver fat in phase 2 study Keith Alcorn / 14 September 2020 Aldafermin significantly reduced liver fat content and liver damage in a phase 2 study of a 24-week treatment course, Dr Stephen Harrison, Visiting Professor of Hepatology at the University of Oxford, told ... NAFLD Fatty liver disease affects one in four in Europe, study estimates Keith Alcorn / 07 September 2020 Non-alcoholic fatty liver disease affects one in four people in the general population in Europe and just over one in twenty people have advanced liver fibrosis, a meta-analysis of 33 studies from ... Antiviral therapy Stopping antivirals may offer a chance for a hepatitis B cure Liz Highleyman / 06 September 2020 Discontinuation of long-term nucleoside/nucleotide antiviral treatment for hepatitis B can allow some people to achieve a cure, according to a pair of presentations last week at the 2020 Digital International Liver Congress. This may happen ... Treatment for hepatocellular carcinoma Immunotherapy combinations show promise for advanced liver cancer Liz Highleyman / 02 September 2020 Three checkpoint inhibitor immunotherapy regimens show promise for people with hepatocellular carcinoma (HCC), the most common type of liver cancer, according to a set of late-breaking presentations last week at the 2020 Digital ... New and experimental treatments for hepatitis B Gilead immune modulator has modest effect on hepatitis B surface antigen Keith Alcorn / 01 September 2020 Selgantolimod, a toll-like receptor agonist designed to enhance immune responses to hepatitis B virus, showed only modest effects on hepatitis B surface antigen levels in a phase 2 safety and efficacy study presented ... Hepatitis delta Bulevirtide shows promise as maintenance therapy for hepatitis D Liz Highleyman / 30 August 2020 High-dose bulevirtide (Hepcludex) combined with pegylated interferon alfa-2a (Pegasys) or tenofovir disoproxil fumarate (TDF; Viread) led to suppression of hepatitis delta virus (HDV), according to a presentation this week at the 2020 Digital International ... View more > Editors' picks from other sources NAFLD Novel methods of non-invasive testing for non-alcoholic fatty liver disease EASL / 28 August 2020 NAFLD Liver fibrosis assessment in routine care for diabetic patients could uncover a hidden population of people living with advanced liver disease EASL / 28 August 2020 Experimental treatments for NASH/NAFLD Two novel treatments show promise in improving biomarkers of NASH pathology EASL / 28 August 2020 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive